CDKN2A and sarcoma: Finally, our findings suggest that patients with TFCP2-rearranged sarcomas, which are refractory to conventional chemotherapy, may benefit from combination treatments that include platinum derivatives, ALK inhibitors, and, in the case of CDKN2A/MTAP co-deletions, drugs targeting PRMT5.